{"filing":{"accession_number":"0001104659-26-099900","cik":"0001720893","ticker":"BTAI","company_name":"BioXcel Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-24","report_date":"2026-08-21","primary_document":"tm2623861d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926099900/tm2623861d1_8k.htm"},"events":[{"id":29038,"run_id":26571,"accession_number":"0001104659-26-099900","anchor_item_number":"1.01","event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The Thirteenth Amendment to the Credit Agreement imposes a mandatory requirement that BioXcel enter into definitive agreements by August 28, 2026 to either repay all loan obligations or execute an alternative capital solutions transaction acceptable to Lenders. This amendment extends a prior deadline (from August 21 to August 28, 2026) and signals that the Company faces a covenant-like triggering event requiring material refinancing or capital restructuring within days. The language \"required to...enter into definitive agreements\" with Lender approval conditions indicates a direct financial obligation acceleration tied to the existing credit facility, characteristic of covenant breach or technical default dynamics.","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-08-24","form":"8-K","submitted_at":null,"items":[{"id":31179,"accession_number":"0001104659-26-099900","item_number":"1.01","item_title":null,"event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Thirteenth Amendment to the Credit Agreement imposes a mandatory requirement that BioXcel enter into definitive agreements by August 28, 2026 to either repay all loan obligations or execute an alternative capital solutions transaction acceptable to Lenders. This amendment extends a prior deadline (from August 21 to August 28, 2026) and signals that the Company faces a covenant-like triggering event requiring material refinancing or capital restructuring within days. The language \"required to...enter into definitive agreements\" with Lender approval conditions indicates a direct financial obligation acceleration tied to the existing credit facility, characteristic of covenant breach or technical default dynamics.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T11:01:36.581242+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31179,"accession_number":"0001104659-26-099900","item_number":"1.01","item_title":null,"event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Thirteenth Amendment to the Credit Agreement imposes a mandatory requirement that BioXcel enter into definitive agreements by August 28, 2026 to either repay all loan obligations or execute an alternative capital solutions transaction acceptable to Lenders. This amendment extends a prior deadline (from August 21 to August 28, 2026) and signals that the Company faces a covenant-like triggering event requiring material refinancing or capital restructuring within days. The language \"required to...enter into definitive agreements\" with Lender approval conditions indicates a direct financial obligation acceleration tied to the existing credit facility, characteristic of covenant breach or technical default dynamics.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T11:01:36.581242+00:00","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-08-24"}]}